Kathleen Davenport is Senior Director of New Product Planning at Surface Oncology, where she leads commercial strategy and planning for all clinical-stage assets. Prior to joining Surface, Kathleen initiated and led New Product Planning at Dicerna Pharmaceuticals, supporting commercial assessment, strategy, and indication prioritization across multiple therapeutic areas, including rare and common diseases. Kathleen was previously at TESARO, where she led competitive intelligence for late-stage clinical programs. She holds a PhD from the University of California, San Diego and San Diego State University and a Bachelors from Boston College.